<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03781401</url>
  </required_header>
  <id_info>
    <org_study_id>TEMPLAR</org_study_id>
    <nct_id>NCT03781401</nct_id>
  </id_info>
  <brief_title>Telemonitoring of Blood Pressure in Local Pharmacies</brief_title>
  <acronym>TEMPLAR</acronym>
  <official_title>Blood Pressure Telemonitoring in Local Pharmacies and Blood Pressure Control in the Community</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Institute of Telemedicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Italian Society of Hypertension</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Italian Society of General Practitioners</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biotechmed Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Italian Institute of Telemedicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TEMPLAR project is an observational, cross-sectional, multicenter study involving several&#xD;
      community pharmacies spread all over Italy. The aim of the project, the currently largest&#xD;
      Italian ABPM Registry, is to analyze the 24-hour ABPMs performed in community pharmacies&#xD;
      enabled for this service in accordance with the current Italian regulations, in order to&#xD;
      evaluate the level of BP control in the community and to provide scientific evidence on the&#xD;
      usefulness of a telehealth network involving the pharmacist for the screening and control of&#xD;
      hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The recent introduction of second-level services in Pharmacy, has resulted in the gradual&#xD;
      diffusion of some techniques, which, under medical supervision, have enormous potential in&#xD;
      improving screening, prevention and control of the most common chronic diseases. Among these&#xD;
      services, 24-hour and home blood pressure monitoring are the most commonly available. The&#xD;
      introduction of blood pressure monitoring in Pharmacy, under medical prescription,&#xD;
      supervision and reporting, plays an important scientific role. As a matter of fact, the&#xD;
      collected data can be useful for taking a picture of the status of the blood pressure control&#xD;
      in a setting different from that of the Hospital or Hypertension Clinic. These data can also&#xD;
      help to evaluate the usefulness of such a service in terms of improvement of public health&#xD;
      and as a support to Doctor's intervention.&#xD;
&#xD;
      The aim of the project is to assess the level of blood pressure control in patients&#xD;
      undergoing 24-hour or home blood pressure monitoring through Pharmacies enabled for this&#xD;
      service in accordance with the current local laws. Specific objectives of the project are: a)&#xD;
      to verify whether such a service is really useful in terms of hypertension screening, b) to&#xD;
      assess the real blood pressure control of hypertensive patients pharmacologically treated, c)&#xD;
      to typify the degree of blood pressure control according to the main demographic and clinical&#xD;
      characteristics of the subjects.&#xD;
&#xD;
      This is an observational, cross-sectional, multicenter study involving Pharmacies spread all&#xD;
      over Italy. These Pharmacies already make use of a telemonitoring and telereporting system&#xD;
      based on 24-hour and home blood pressure monitoring, with centralized data collection. The&#xD;
      service is developed in accordance with the rules governing the second-level services payable&#xD;
      in Pharmacy (DL 03/10/2009 n. 153 and DM 16/12/2010) and with the legislation on protection&#xD;
      of personal data (DL 30/06/2003 n. 196). The service is provided in accordance with the&#xD;
      current Guidelines of the Italian Society of Hypertension and the European Society of&#xD;
      Hypertension and is managed by Doctors expert of the methodology. The service is offered to&#xD;
      patients upon payment and the test is prescribed by the General Practitioner (referring&#xD;
      physician of the patient). The data collected as part of the service provided by the single&#xD;
      Pharmacies are analyzed for the purposes of the Project. The project foresees the analysis of&#xD;
      blood pressure recordings and clinical data of subjects of both sexes, aged ≥ 18 years,&#xD;
      undergoing a 24-hour or home blood pressure monitoring because of a suspected hypertension&#xD;
      (patients not pharmacologically treated) or to verify the degree of blood pressure control&#xD;
      with antihypertensive drug therapy (patients under treatment).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2010</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>24-hour blood pressure control rate</measure>
    <time_frame>10 years</time_frame>
    <description>The percentage of patients with an average 24-hour blood pressure &lt;130/80 mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Office blood pressure control rate</measure>
    <time_frame>10 years</time_frame>
    <description>The percentage of patients with an office blood pressure &lt;140/90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day-time blood pressure control rate</measure>
    <time_frame>10 years</time_frame>
    <description>The percentage of patients with an average day-time blood pressure &lt;135/85 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night-time blood pressure control</measure>
    <time_frame>10 years</time_frame>
    <description>The percentage of patients with an average night-time blood pressure &lt;120/70 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of blood pressure control in treated vs. untreated subjects</measure>
    <time_frame>10 years</time_frame>
    <description>The percentage of treated vs. untreated patients with blood pressure control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with white-coat hypertension</measure>
    <time_frame>10 years</time_frame>
    <description>Percentage of patients with an office SBP ≥140 mmHg and/or DBP ≥90 mmHg + 24-hour average BP &lt;130/80 mmHg + day-time average BP &lt;135/85 mmHg + night-time average BP &lt;120/70 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with masked hypertension</measure>
    <time_frame>10 years</time_frame>
    <description>Percentage of patients with an office BP &lt;140/90 mmHg + 24-hour average SBP ≥130 mmHg and/or DBP ≥80 mmHg or day-time average SBP ≥135 mmHg and/or DBP ≥85 mmHg or night-time average SBP ≥120 mmHg and/or DBP ≥70 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure control in subgroups at risk</measure>
    <time_frame>10 years</time_frame>
    <description>Rate of office and ambulatory blood pressure control according to sex, age, cardiovascular risk factors and concomitant diseases</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40000</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ambulatory blood pressure monitoring</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients of both sexes and of any age with conventional clinical indications&#xD;
        for ABPM (either treated with antihypertensive drugs or untreated) referred to the pharmacy&#xD;
        by their family doctors for diagnostic purposes (established or suspected arterial&#xD;
        hypertension).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive patients of both sexes and of any age&#xD;
&#xD;
          -  Conventional clinical indications for ABPM (either treated with antihypertensive drugs&#xD;
             or untreated)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Omboni, MD</last_name>
    <role>Study Director</role>
    <affiliation>Italian Institute of Telemedicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Omboni, MD</last_name>
    <phone>+390331984176</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Italian Institute of Telemedicine</name>
      <address>
        <city>Solbiate Arno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Omboni</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.templarnet.org</url>
    <description>The official website of the TEMPLAR project with updates on the status of the study and current findings.</description>
  </link>
  <link>
    <url>http://www.tholomeus.net</url>
    <description>The certified web-based telemedicine platform used to collect the data for the TEMPLAR Project.</description>
  </link>
  <results_reference>
    <citation>Omboni S, Mancinelli A, Rizzi F, Parati G; TEMPLAR (TEleMonitoring of blood Pressure in Local phARmacies) Project Group. Telemonitoring of 24-Hour Blood Pressure in Local Pharmacies and Blood Pressure Control in the Community: The Templar Project. Am J Hypertens. 2019 Jun 11;32(7):629-639. doi: 10.1093/ajh/hpz049.</citation>
    <PMID>30976783</PMID>
  </results_reference>
  <results_reference>
    <citation>Omboni S, Tenti M. Telepharmacy for the management of cardiovascular patients in the community. Trends Cardiovasc Med. 2019 Feb;29(2):109-117. doi: 10.1016/j.tcm.2018.07.002. Epub 2018 Jul 12. Review.</citation>
    <PMID>30037524</PMID>
  </results_reference>
  <results_reference>
    <citation>Omboni S, Caserini M, Coronetti C. Telemedicine and M-Health in Hypertension Management: Technologies, Applications and Clinical Evidence. High Blood Press Cardiovasc Prev. 2016 Sep;23(3):187-96. doi: 10.1007/s40292-016-0143-6. Epub 2016 Apr 12. Review.</citation>
    <PMID>27072129</PMID>
  </results_reference>
  <results_reference>
    <citation>Omboni S, Sala E. The pharmacist and the management of arterial hypertension: the role of blood pressure monitoring and telemonitoring. Expert Rev Cardiovasc Ther. 2015 Feb;13(2):209-21. doi: 10.1586/14779072.2015.1001368. Epub 2015 Jan 12. Review.</citation>
    <PMID>25578090</PMID>
  </results_reference>
  <results_reference>
    <citation>Omboni S, Campolo L, Panzeri E. Telehealth in chronic disease management and the role of the Internet-of-Medical-Things: the Tholomeus® experience. Expert Rev Med Devices. 2020 Jul;17(7):659-670. doi: 10.1080/17434440.2020.1782734. Epub 2020 Jun 30. Review.</citation>
    <PMID>32536214</PMID>
  </results_reference>
  <results_reference>
    <citation>Omboni S, Panzeri E, Campolo L. E-Health in Hypertension Management: an Insight into the Current and Future Role of Blood Pressure Telemonitoring. Curr Hypertens Rep. 2020 Jun 6;22(6):42. doi: 10.1007/s11906-020-01056-y. Review.</citation>
    <PMID>32506273</PMID>
  </results_reference>
  <results_reference>
    <citation>Omboni S, McManus RJ, Bosworth HB, Chappell LC, Green BB, Kario K, Logan AG, Magid DJ, Mckinstry B, Margolis KL, Parati G, Wakefield BJ. Evidence and Recommendations on the Use of Telemedicine for the Management of Arterial Hypertension: An International Expert Position Paper. Hypertension. 2020 Nov;76(5):1368-1383. doi: 10.1161/HYPERTENSIONAHA.120.15873. Epub 2020 Sep 14. Review.</citation>
    <PMID>32921195</PMID>
  </results_reference>
  <results_reference>
    <citation>Omboni S, Ballatore T, Rizzi F, Tomassini F, Campolo L, Panzeri E. Feasibility of 24-h blood pressure telemonitoring in community pharmacies: the TEMPLAR project. J Hypertens. 2021 Oct 1;39(10):2075-2081. doi: 10.1097/HJH.0000000000002895.</citation>
    <PMID>34102664</PMID>
  </results_reference>
  <results_reference>
    <citation>Omboni S, Ballatore T, Rizzi F, Tomassini F, Panzeri E, Campolo L. Telehealth at scale can improve chronic disease management in the community during a pandemic: An experience at the time of COVID-19. PLoS One. 2021 Sep 29;16(9):e0258015. doi: 10.1371/journal.pone.0258015. eCollection 2021.</citation>
    <PMID>34587198</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 18, 2018</study_first_submitted>
  <study_first_submitted_qc>December 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

